EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

MST2 methylation by PRMT5 inhibits Hippo signaling and promotes pancreatic cancer progression

Yan Sun, Xin Jin iD, Junpeng Meng, Feng Guo iD, Taoyu Chen, Xiaoyan Zhao iD, Heshui Wu iD, Dianyun Ren iD

The EMBO Journal · 2023

DOI: 10.15252/embj.2023114558 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The EMBO Journal, 2023. Verfasst von Yan Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Hippo Signaling Pathway, Pancreatic Neoplasms. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: | Natural Science Foundation of Shanxi Province (Shanxi Natural Science Foundation), MOST | National Natural Science Foundation of China (NSFC), 山西省科学技术厅 | Natural Science Foundation of Shanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Hippo signaling axis is a tumor suppressor pathway that is activated by various extra-pathway factors to regulate cell differentiation and organ development. Recent studies have reported that autophosphorylation of the core kinase cassette stimulates activation of the Hippo signaling cascade. Here, we demonstrate that protein arginine methyltransferase 5 (PRMT5) contributes to inactivation of the Hippo signaling pathway in pancreatic cancer. We show that the Hippo pathway initiator serine/threonine kinase 3 (STK3, also known as MST2) of Hippo signaling pathway can be symmetrically di-methylated by PRMT5 at arginine-461 (R461) and arginine-467 (R467) in its SARAH domain. Methylation suppresses MST2 autophosphorylation and kinase activity by blocking its homodimerization, thereby inactivating Hippo signaling pathway in pancreatic cancer. Moreover, we also show that the specific PRMT5 inhibitor GSK3326595 re-activates the dysregulated Hippo signaling pathway and inhibits the growth of human pancreatic cancer xenografts in immunodeficient mice, thus suggesting potential clinical application of PRMT5 inhibitors in pancreatic cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hippo Signaling PathwayPancreatic NeoplasmsHumansMiceAnimalsProtein Serine-Threonine KinasesSignal TransductionMethylationArginineSerine-Threonine Kinase 3Protein-Arginine N-MethyltransferasesHippo Kinases

Stichwörter der Autor:innen

MST2PRMT5dimerizationmethylationpancreatic cancer

Substanzen

Protein Serine-Threonine KinasesArginineSerine-Threonine Kinase 3Protein-Arginine N-MethyltransferasesSTK3 protein, humanHippo KinasesPRMT5 protein, human

Autor:innen und Institutionen

  • Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Sino-German Laboratory of Personalized Medicine for Pancreatic Cancer, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Uro-Oncology Institute of Central South University, Changsha, China.
  • Department of General Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, China.
  • Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Xin Jin, Feng Guo, Xiaoyan Zhao, Heshui Wu, Dianyun Ren

Förderung

  • | Natural Science Foundation of Shanxi Province (Shanxi Natural Science Foundation)
  • MOST | National Natural Science Foundation of China (NSFC)
  • 山西省科学技术厅 | Natural Science Foundation of Shanxi Province

Zitieren

APA

Sun, Y., Jin, X., Meng, J., Guo, F., Chen, T., Zhao, X., Wu, H., & Ren, D. (2023). MST2 methylation by PRMT5 inhibits Hippo signaling and promotes pancreatic cancer progression. The EMBO Journal. https://doi.org/10.15252/embj.2023114558

Vancouver

Sun Y, Jin X, Meng J, Guo F, Chen T, Zhao X, et al. MST2 methylation by PRMT5 inhibits Hippo signaling and promotes pancreatic cancer progression. The EMBO Journal. 2023. doi:10.15252/embj.2023114558

BibTeX
@article{Sun2023,
  author = {Sun, Yan and Jin, Xin and Meng, Junpeng and Guo, Feng and Chen, Taoyu and Zhao, Xiaoyan and Wu, Heshui and Ren, Dianyun},
  title = {MST2 methylation by PRMT5 inhibits Hippo signaling and promotes pancreatic cancer progression},
  journal = {The EMBO Journal},
  year = {2023},
  doi = {10.15252/embj.2023114558}
}
Kostenlos starten →